Bracco News 
and Press Center 

Bracco Diagnostics Inc. announced today that the results of a nationwide real-world study, published by Dr. Strom et al. in the Journal of the American Heart Association on 14 May 2025, provide valuable information on safety outcomes of cardiac ultrasound procedures in contemporary practice in the United States.

Bracco Diagnostics Inc. announced today significant upgrades to its innovative HeartSee^TM software, a leading diagnostic tool used in myocardial blood flow (MBF) quantification with cardiac positron emission tomography (PET) imaging.

Bracco Imaging announced today that the U.S. FDA has granted Fast Track designation for the development of BR55 (perfluorobutane/nitrogen lipopeptide-coated microbubbles) injection for detecting areas of active bowel inflammation in patients with Crohn's disease.

Bracco Diagnostics expands its VARIBAR® product line with barium sulfate MINIS for improved diagnostic swallow studies and patient compliance.

Bracco Diagnostics Inc. Branded Max 3^TM, a Rapid Exchange and Syringeless Injector, received FDA 510(k) clearance adding evolving innovation in Magnetic Resonance Imaging (MRI) and its product portfolio.

To learn more, visit Bracco’s booth #3300 at the Radiological Society of North America (RSNA) 2024 Annual Meeting, to be held from December 1-5 in Chicago, Illinois

Bracco Diagnostics Inc. is proud to announce that its most recently FDA-approved magnetic resonance imaging (MRI) agent, VUEWAY^® (gadopiclenol) solution for injection, has reached over one million patient injections at over 480 customer sites.

Explore the advanced diagnostic imaging solutions Bracco presented at RSNA 2024, including contrast agents, injectors, and AI-driven tools.

Bracco announces FDA clearance for AiMIFY™ software, improving efficiency in molecular imaging interpretation and workflow.

Discover Bracco’s participation at RSNA 2024, showcasing groundbreaking diagnostic imaging solutions and educational programs for radiologists worldwide.
 

Discover Bracco’s launch of CitraClear™, a preprocedure hydration beverage designed with patients in mind.

Strategic decisions enable Bracco to serve better the needs of healthcare providers and patients with its enhanced pipeline offering.

Bracco is proud to renew its three-year unrestricted educational grant commitment as the sole partner of the SABI Mentorship Program. The objective of the program is to support the career growth and personal development of SABI members.

Meet the innovators recognized by Applied Radiology’s “Leaders on the Horizon” program and how they’re shaping the future of medical imaging.

Join Bracco at RSNA 2023 to explore our latest innovations in medical imaging, including AI-driven tools and advanced contrast agents.
 

Learn about Bracco’s iodine recollection pilot program and Re.Viva initiative, advancing sustainability and circular economy in diagnostic imaging.

Discover why ACR designated Gadopiclenol as a Group II agent and what this means for patient safety and diagnostic accuracy in MRI imaging.

Preeminent Hospitals and Medical Practices Nationwide Lead in Patient Care with First Use of Bracco’s VUEWAY™ (gadopiclenol) solution for injection for MRI.

The results of the multicenter, multinational PICTURE clinical trial demonstrate that 0.05 mmol/kg gadopiclenol provides similar morphologic information about CNS lesions and greater contrast enhancement compared with 0.1 mmol/kg gadobutrol.

A new survey reveals that 55% of radiologists are concerned about contrast agent supply—see how Bracco addresses these critical challenges in healthcare.

Bracco provides a temporary importation of Iomeron® contrast agent to address supply challenges and ensure continuity in patient care.

We are thrilled to open the doors of our “digital house” created by our people and inhabited by our stories

Radiology residents receive scholarship, research publication in Applied Radiology supplement, and invite to RSNA reception.

Alberto Spinazzi, Bracco Chief Medical and Regulatory Officer, answers some of these questions by illustrating future trends and the importance of prevention for human health.

Talking Images podcast: The sustainable way – voices of action. What do environmental sustainability and sustainable future mean?

Bracco Announces FDA Approval of Gadopiclenol Injection, a New Macrocyclic High-Relaxivity Gadolinium-Based Contrast Agent which will be commercialized as VUEWAY™ (gadopiclenol) injection and VUEWAY™ (gadopiclenol) Pharmacy Bulk Package by Bracco.

BIPSO sets the course for sterile contrast media production according to the latest environmental standards.

The astounding Bracco story unfolds across archives that have been thematically divided into five sections: Family, Company, Innovation, Sustainability, and Culture.

Bracco Imaging and Guerbet have a worldwide collaboration on Gadopiclenol, an investigational macrocyclic gadolinium-based contrast agent (GBCA).

95 grants to celebrate Bracco’s 95th Anniversary

The US shortage crisis: Bracco Imaging’s CEO statement on New York Times

A new customised nanomedicine project to fight cancer, a new therapy that includes pre-treating

They have left the war in Ukraine behind and have been welcomed in Italy by the Bracco Group in collaboration with the Town of Cesano and the local community.

Shaharzad Akbar arrived from Rome where she had provided testimony during a meeting of Italy’s Chamber of Deputies and Senate Joint Committee on Foreign Affairs.

Some of the goals in a Policy Paper drafted by the B20 Special Initiative on Women’s Empowerment.

Trieste Next Festival: Diana Bracco and Gianvito Vilé talk about scientific research and the brain drain.

The Bracco Foundation: ten years in the name of culture, science and social engagement.

Stay plugged in to the latest developments—for radiologists, imagine: rather than generating a text report for a referring physician, you could show them your workstation directly.

Is AI the elephant in the radiology suite? A 2019 report from the Dana-Farber Cancer Institute showcased an artificial intelligence tool that performed as well as human reviewers—and much more rapidly.

Explore why nuclear medicine is projected to reach over $12B by 2025 and Bracco’s role in shaping the future of diagnostic and therapeutic imaging solutions.